Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

1. Gilead reported Q2 2025 earnings of $2.01 per share, exceeding $1.94 consensus. 2. Sales reached $7.08 billion, surpassing the $6.94 billion forecast. 3. Biktarvy sales rose 9% to $3.5 billion; Descovy sales increased 35%. 4. Gilead initiated a $6 billion stock repurchase program to enhance shareholder value. 5. Analysts expect positive stock performance driven by upcoming drug launches.